Correction: miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer

Yinghong Pan; Gordon Robertson; Lykke Pedersen; Emilia Lim; Anadulce Hernandez-Herrera; Amy C. Rowat; Sagar L. Patil; Clara K. Chan; Yunfei Wen; Xinna Zhang; Upal Basu-Roy; Alka Mansukhani; Andy Chu; Payal Sipahimalani; Reanne Bowlby; Denise Brooks; Nina Thiessen; Cristian Coarfa; Yussanne Ma; Richard A. Moore; Jacquie E. Schein; Andrew J. Mungall; Jinsong Liu; Chad V. Pecot; Anil K. Sood; Steven J.M. Jones; Marco A. Marra; Preethi H. Gunaratne

doi:10.18632/oncotarget.15921

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer

Yinghong Pan, Gordon Robertson, Lykke Pedersen, Emilia Lim, Anadulce Hernandez-Herrera, Amy C. Rowat, Sagar L. Patil, Clara K. Chan, Yunfei Wen, Xinna Zhang, Upal Basu-Roy, Alka Mansukhani, Andy Chu, Payal Sipahimalani, Reanne Bowlby, Denise Brooks, Nina Thiessen, Cristian Coarfa, Yussanne Ma, Richard A. Moore, Jacquie E. Schein, Andrew J. Mungall, Jinsong Liu, Chad V. Pecot, Anil K. Sood, Steven J.M. Jones, Marco A. Marra and Preethi H. Gunaratne _

PDF | How to cite

Oncotarget. 2017; 8:17406-17406. https://doi.org/10.18632/oncotarget.15921

Metrics: PDF 2450 views | ?

Present:

ACKNOWLEDGEMENTS

The authors gratefully acknowledge the data production teams at the Genome Sciences Centre.

Corrected:

ACKNOWLEDGEMENTS

Corrected: The authors gratefully acknowledge the data production teams at the Genome Sciences Centre. The results published here are in whole or part based upon data generated by The Cancer Genome Atlas managed by the NCI and NHGRI. Information about TCGA can be found at http://cancergenome.nih.gov.

Original article: Oncotarget. 2016; 7(18):25930-48. DOI: 10.18632/oncotarget.8412.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15921

Publication Alerts

Corrections:

Correction: miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer